Conclusions: There may be a significantly different response to PDT between two angiographic phenotypes of PCV. (C) 2014 S. Karger AG, Basel”
“Background: Polio eradication remains a challenge in Pakistan and the causes for the failure to eradicate poliomyelitis are complex. Undernutrition and micronutrient deficiencies, especially zinc deficiency, are major public health problems in Pakistan and could potentially affect the response to enteric vaccines, including oral poliovirus vaccine (OPV). Objective: To assess the impact of zinc supplementation among infants on immune response to oral poliovirus A1155463 vaccine (OPV). Methods: A

double-blind, randomized placebo-controlled trial was conducted in newborns (aged 0-14 days). Subjects were assigned to either receive 10 mg of zinc or placebo supplementation daily for 18 weeks. Both groups received OPV doses at birth, at 6 weeks, 10 weeks and 14 weeks. Data was collected on prior immunization status, diarrheal episodes, breastfeeding practices and anthropometric measurements at recruitment and at 6 and 18 weeks. Blood samples were similarly collected to determine the

antibody response to OPV and for micronutrient analysis. Logistic Bcl-2 apoptosis pathway regression was used to determine the relationship between seroconversion and zinc status. Results: Overall, 404 subjects were recruited. At recruitment, seropositivity was already high for poliovirus (PV) serotype 1 (zinc: 91.1%; control: 90.5%) and PV2 (90.0%; 92.7%), with lower estimates for PV3 (70.0%; 64.8%).

By week 18, the proportion of subjects with measured zinc levels in the normal range (i.e. bigger than = 60 mu g/dL) was significantly greater in the intervention group compared to the control group (71.9%; 27.4%; p smaller than 0.001). No significant difference in seroconversion was demonstrated between the groups for PV1, PV2, or PV3. Conclusions: There was no effect of zinc supplementation on OPV immunogenicity. These conclusions were confirmed when restricting the analysis to those with measured higher zinc levels. (C) 2014 Elsevier Ltd. All rights reserved.”
“Accumulation ALK inhibitor of the DNA/RNA binding protein fused in sarcoma as cytoplasmic inclusions in neurons and glial cells is the pathological hallmark of all patients with amyotrophic lateral sclerosis with mutations in FUS as well as in several subtypes of frontotemporal lobar degeneration, which are not associated with FUS mutations. The mechanisms leading to inclusion formation and fused in sarcoma-associated neurodegeneration are only poorly understood. Because fused in sarcoma belongs to a family of proteins known as FET, which also includes Ewing’s sarcoma and TATA-binding protein-associated factor 15, we investigated the potential involvement of these other FET protein family members in the pathogenesis of fused in sarcoma proteinopathies.